Pharmaceutical Preparations
Standard Industrial Classification: SIC 2834
Industry Insider Sentiment Analysis
The Pharmaceutical Preparations sector (SIC 2834) acts as a critical barometer for broader economic health. Our real-time monitoring reveals total transactions. Monitoring "cluster buying" is one of the most reliable leading indicators for future sector performance. By analyzing aggregate data across this specific Standard Industrial Classification, investors can filter out individual company volatility and identify high-conviction trends. When multiple directors and officers within the same industry move capital simultaneously, it often signals an upcoming sector-wide revaluation or a fundamental shift in supply chain dynamics that has yet to be recognized by the broader public market.
| Filing Date | Trade Date | Ticker | Company | Reporting Person | Relationship | Type | Price | Qty | Total, $ | Owned After |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-29 02:51 | 2025-10-28 | VKTX | Viking Therapeutics, Inc. | Mancini Marianna | Officer | SELL | $35.00 | 6,185 | $216,492 | 382,467 |
| 2025-10-29 02:48 | 2025-10-28 | VKTX | Viking Therapeutics, Inc. | Lian Brian | Director, Officer | SELL | $35.01 | 38,989 | $1,364,923 | 2,419,109 |
| 2025-10-28 23:10 | 2025-10-27 | MRSN | Mersana Therapeutics, Inc. | Bala Mohan | Officer | OPT+S | $9.90 | 77 | $762 | 2,922 |
| 2025-10-29 01:45 | 2025-10-24 | RNTX | Rein Therapeutics, Inc. | Voss Capital, LP | 10% owner | BUY | $1.38 | 306,050 | $423,451 | 500,000 |
| 2025-10-29 00:00 | 2025-10-24 | CVKD | Cadrenal Therapeutics, Inc. | Pham Quang X | Director, Officer, 10% owner | SELL | $14.01 | 2,444 | $34,237 | 196,089 |
| 2025-10-29 00:00 | 2025-10-24 | CVKD | Cadrenal Therapeutics, Inc. | Szot Matthew K | Officer | SELL | $13.99 | 3,600 | $50,364 | 9,933 |
| 2025-10-29 02:49 | 2025-10-27 | VKTX | Viking Therapeutics, Inc. | Rowland Charles A Jr | Director | OPT+S | $35.57 | 60,000 | $2,134,278 | 30,000 |
| 2025-10-29 04:05 | 2025-10-24 | SION | Sionna Therapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | SELL | $39.51 | 373,610 | $14,762,601 | 209,391 |
| 2025-10-28 20:22 | 2025-10-27 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Officer | OPT+S | $5.19 | 949 | $4,921 | 0 |
| 2025-10-29 02:47 | 2025-10-28 | VKTX | Viking Therapeutics, Inc. | ZANTE GREG | Officer | SELL | $35.00 | 6,185 | $216,481 | 173,592 |
| 2025-10-29 01:00 | 2025-10-24 | BGMS | Bio Green Med Solution, Inc. | Ong Yee Lung | 10% owner | SELL | $1.99 | 19,858 | $39,517 | 248,814 |
| 2025-10-29 01:00 | 2025-10-24 | BGMS | Bio Green Med Solution, Inc. | Yap Kim Choy | 10% owner | SELL | $1.90 | 19,595 | $37,270 | 384,870 |
| 2025-10-28 23:30 | 2025-10-27 | UTHR | UNITED THERAPEUTICS Corp | BENKOWITZ MICHAEL | Officer | OPT+S | $417.50 | 22,500 | $9,393,671 | 130 |
| 2025-10-28 02:56 | 2025-10-27 | CNTA | Centessa Pharmaceuticals plc | Accardi Mario Alberto | Officer | OPT+S | $25.00 | 8,000 | $200,000 | 194,394 |
| 2025-10-27 23:15 | 2025-10-23 | TNGX | Tango Therapeutics, Inc. | Third Rock Ventures IV, L.P. | 10% owner | SELL | $10.15 | 477,401 | $4,846,575 | 13,386,574 |
| 2025-10-27 23:23 | 2025-10-24 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Cohen Yuval | Director, Officer | OPT+S | $17.05 | 27,633 | $471,203 | 138,187 |
| 2025-10-27 23:30 | 2025-10-23 | VRDN | Viridian Therapeutics, Inc.\DE | Fairmount Funds Management LLC | Director, 10% owner | BUY | $22.00 | 454,545 | $9,999,990 | 3,914,458 |
| 2025-10-27 23:22 | 2025-10-24 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Moran Sean F. | Officer | OPT+S | $17.02 | 12,981 | $220,937 | 73,313 |
| 2025-10-28 04:30 | 2025-10-23 | CRMD | CorMedix Inc. | Kaplan Myron | Director | BUY | $11.02 | 25,000 | $275,500 | 201,034 |
| 2025-10-27 23:30 | 2025-10-23 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer | OPT+S | $423.12 | 8,000 | $3,384,989 | 130 |
| 2025-10-28 00:59 | 2025-10-27 | CYTK | CYTOKINETICS INC | WIERENGA WENDELL | Director | OPT+S | $58.68 | 4,375 | $256,725 | 32,444 |
| 2025-10-28 00:19 | 2025-10-23 | PMVP | PMV Pharmaceuticals, Inc. | ORBIMED ADVISORS LLC | 10% owner | SELL | $1.52 | 1,000,000 | $1,520,000 | 4,975,291 |
| 2025-10-28 02:24 | 2025-10-23 | RANI | Rani Therapeutics Holdings, Inc. | IMRAN MIR A | Director, 10% owner | BUY | $0.61 | 2,083,334 | $1,260,417 | 2,083,334 |
| 2025-10-24 23:30 | 2025-10-23 | ALZN | Alzamend Neuro Inc. | McGrath Lynne Fahey | Director | SELL | $2.29 | 30 | $69 | 25 |
| 2025-10-25 02:19 | 2025-06-06 | BOLT | Bolt Biotherapeutics, Inc. | Nemec Sarah | Officer | BUY | $5.49 | 125 | $687 | 943 |
| 2025-10-25 02:18 | 2025-06-06 | BOLT | Bolt Biotherapeutics, Inc. | Quinn William P. | Director, Officer | BUY | $5.49 | 125 | $687 | 2,188 |
| 2025-10-24 23:56 | 2025-10-22 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Officer | OPT+S | $47.54 | 2,209 | $105,015 | 38,867 |
| 2025-10-25 03:00 | 2025-10-22 | KALA | KALA BIO, Inc. | Kharabi Darius | Officer | SELL | $0.83 | 20,806 | $17,269 | 41,760 |
| 2025-10-25 03:00 | 2025-10-22 | KALA | KALA BIO, Inc. | Reumuth Mary | Officer | SELL | $0.83 | 33,197 | $27,544 | 28,906 |
| 2025-10-25 03:00 | 2025-10-22 | KALA | KALA BIO, Inc. | Bazemore Todd | Director | SELL | $0.83 | 47,768 | $39,647 | 35,932 |
| 2025-10-25 03:00 | 2025-10-23 | KALA | KALA BIO, Inc. | Iwicki Mark T | Director | SELL | $0.81 | 154,894 | $125,464 | 103,540 |
| 2025-10-24 23:01 | 2025-10-22 | IRON | Disc Medicine, Inc. | AI DMI LLC | 10% owner | SELL | $80.47 | 744,047 | $59,873,462 | 2,814,379 |
| 2025-10-25 03:00 | 2025-10-22 | KALA | KALA BIO, Inc. | Brazzell Romulus K | Officer | SELL | $0.83 | 46,748 | $38,801 | 35,952 |
| 2025-10-25 03:18 | 2025-10-22 | GALT | GALECTIN THERAPEUTICS INC | 10X Fund, L.P. | 10% owner | SELL | $4.94 | 50,000 | $246,800 | 5,872,207 |
| 2025-10-25 02:06 | 2025-10-22 | PAHC | PHIBRO ANIMAL HEALTH CORP | BENDHEIM JACK | Director, Officer, 10% owner | SELL | $40.53 | 18,899 | $765,941 | 55,000 |
| 2025-10-24 04:03 | 2025-10-23 | TTRX | Turn Therapeutics Inc. | Chaudhary Zuraiz | Officer | BUY | $4.95 | 5,050 | $24,998 | 5,050 |
| 2025-10-24 04:06 | 2025-10-21 | SMMT | Summit Therapeutics Inc. | Xia Yu | Director | BUY | $18.74 | 533,617 | $9,999,983 | 32,057,147 |
| 2025-10-23 23:06 | 2025-10-21 | SMMT | Summit Therapeutics Inc. | Zanganeh Mahkam | Director, Officer, 10% owner | BUY | $18.74 | 26,680 | $499,983 | 76,680 |
| 2025-10-23 23:20 | 2025-10-21 | APLS | Apellis Pharmaceuticals Inc. | Sullivan Timothy Eugene | Officer | OPT+S | $28.03 | 10,000 | $280,300 | 110,936 |
| 2025-10-24 02:49 | 2025-10-21 | NEUP | Neuphoria Therapeutics Inc. | Lynx1 Capital Management LP | 10% owner | BUY | $5.14 | 639,110 | $3,283,108 | 875,328 |
| 2025-10-24 01:00 | 2025-10-21 | BGMS | Bio Green Med Solution, Inc. | FITTERS Diversified Berhad | 10% owner | SELL | $3.01 | 92,352 | $277,518 | 279,248 |
| 2025-10-23 23:08 | 2025-10-21 | SMMT | Summit Therapeutics Inc. | DUGGAN ROBERT W | Director, Officer, 10% owner | BUY | $18.74 | 26,680 | $499,983 | 76,680 |
| 2025-10-24 04:01 | 2025-10-23 | TTRX | Turn Therapeutics Inc. | GOLDEN ARTHUR F | Director | BUY | $4.95 | 20,202 | $100,000 | 30,202 |
| 2025-10-22 23:32 | 2025-10-20 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | Officer | OPT+S | $94.91 | 5,000 | $474,550 | 49,086 |
| 2025-10-23 01:57 | 2025-10-20 | RANI | Rani Therapeutics Holdings, Inc. | South Cone Investments Limited Partnership | 10% owner | SELL | $2.65 | 5,923,000 | $15,711,350 | 2,379,194 |
| 2025-10-23 00:39 | 2025-10-21 | SION | Sionna Therapeutics, Inc. | Cloonan Michael | Director, Officer | OPT+S | $36.26 | 99,800 | $3,618,558 | 547,343 |
| 2025-10-23 02:20 | 2025-10-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | Officer | SELL | $22.08 | 12,500 | $276,025 | 915,188 |
| 2025-10-23 00:09 | 2025-10-20 | KNSA | Kiniksa Pharmaceuticals International, plc | Patel Sanj K | Director, Officer | OPT+S | $38.86 | 257,969 | $10,023,540 | 111,794 |
| 2025-10-23 00:06 | 2025-10-20 | KNSA | Kiniksa Pharmaceuticals International, plc | Megna Michael R | Officer | OPT+S | $38.87 | 50,490 | $1,962,784 | 27,046 |
| 2025-10-23 01:00 | 2025-10-20 | BGMS | Bio Green Med Solution, Inc. | FITTERS Diversified Berhad | 10% owner | SELL | $3.09 | 108,107 | $333,834 | 371,600 |
Sector-Wide Insider Alpha
Analyzing insider movements across the Pharmaceutical Preparations sector provides a macro-view of executive conviction. When multiple leaders in different companies within the same SIC code (2834) simultaneously buy shares, it often indicates an industry-wide undervaluation or a positive shift in market cycles.
SEC Filings in Pharmaceutical Preparations
Every transaction in the Pharmaceutical Preparations industry is reported via Form 4 disclosures. By filtering these filings by industry, investors can detect institutional-scale sentiment shifts before they are reflected in broader market indices, following the capital flow of those with intimate industry knowledge.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.